Article

Consumption of the Putative Chemopreventive Agent Curcumin by Cancer Patients: Assessment of Curcumin Levels in the Colorectum and their Pharmacodynamic Consequences

Department of Oncology, RKCSB, LRI, University of Leicester, Leicester, LE2 7LX, United Kingdom.
Cancer Epidemiology Biomarkers & Prevention (Impact Factor: 4.32). 02/2005; 14(1):120-5.
Source: PubMed

ABSTRACT Curcumin, a constituent of the spice turmeric, has been shown to reduce the adenoma burden in rodent models of colorectal cancer accompanied by a reduction of levels of the oxidative DNA adduct 3-(2-deoxy-beta-di-erythro-pentafuranosyl)-pyr[1,2-alpha]-purin-10(3H)one (M(1)G) and of expression of the enzyme cyclooxygenase-2 (COX-2). We tested the hypothesis that pharmacologically active levels of curcumin can be achieved in the colorectum of humans as measured by effects on levels of M(1)G and COX-2 protein. Patients with colorectal cancer ingested curcumin capsules (3,600, 1,800, or 450 mg daily) for 7 days. Biopsy samples of normal and malignant colorectal tissue, respectively, were obtained at diagnosis and at 6 to 7 hours after the last dose of curcumin. Blood was taken 1 hour after the last dose of curcumin. Curcumin and its metabolites were detected and quantitated by high-performance liquid chromatography with detection by UV spectrophotometry or mass spectrometry. M(1)G levels and COX-2 protein expression were measured by immunoslot blot and Western blotting, respectively. The concentrations of curcumin in normal and malignant colorectal tissue of patients receiving 3,600 mg of curcumin were 12.7 +/- 5.7 and 7.7 +/- 1.8 nmol/g, respectively. Curcumin sulfate and curcumin glucuronide were identified in the tissue of these patients. Trace levels of curcumin were found in the peripheral circulation. M(1)G levels were 2.5-fold higher in malignant tissue as compared with normal tissue (P < 0.05 by ANOVA). Administration of curcumin (3,600 mg) decreased M(1)G levels from 4.8 +/- 2.9 adducts per 107 nucleotides in malignant colorectal tissue to 2.0 +/- 1.8 adducts per 107 nucleotides (P < 0.05 by ANOVA). COX-2 protein levels in malignant colorectal tissue were not affected by curcumin. The results suggest that a daily dose of 3.6 g curcumin achieves pharmacologically efficacious levels in the colorectum with negligible distribution of curcumin outside the gut.

Download full-text

Full-text

Available from: Giuseppe Garcea, Mar 20, 2015
0 Followers
 · 
71 Views
  • Source
    • "Curcumin is conjugated to produce curcumin glucuronides and sulfates or it is reduced to hexahydrocurcumin in the liver or in the intestine . The intra-peritoneal or systemic administration leads to the reduction of curcumin into tetrahydrocurcumin, hexahydrocurcumin and octahydrocurcumin (Ireson et al. 2002; Garcea et al. 2005). Curcumin has lower stability and can degrade under physiological conditions. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The management of osteoarthritis represents a real challenge. This complex and multi-factorial disease evolves over decades and requires not only the alleviation of symptoms, i.e. pain and joint function but also the preservation of articular structure without side effects. Nutraceuticals are good candidates for the management of OA due to their safety profile and potential efficacy. However, they are not part of the treatment guidelines and published recommendations. Curcumin is the yellow pigment isolated from the rhizomes of Curcuma longa, commonly known as turmeric. Curcumin is a highly pleiotropic molecule with an excellent safety profile. Strong molecular evidence has been published for its potency to target multiple inflammatory diseases. However, naturally occurring curcumin cannot achieve its optimum therapeutic outcomes due to its low solubility and poor bioavailability. Nevertheless, curcumin presents great potential for treating OA and has been categorized as having preclinical evidence of efficacy. This review aimed at gathering most of the available information to document the potential efficacy of curcumin based on the results obtained in in vitro models of cartilage and osteoarthritis and in other diseases.
    SpringerPlus 12/2013; 2(1):56. DOI:10.1186/2193-1801-2-56
  • Source
    • "ported to have a rapid absorption with a peak plasma half - life . Despite the lower bioavailability , the therapeutic efficacy of curcumin against various human diseases , including cardiovas - cular and neurological diseases ( Aggarwal et al . , 2009 ) , diabetes ( Usharani et al . , 2008 ) , arthritis ( Venkatesha et al . , 2011 ) , can - cer ( Garcea et al . , 2005 ) , and Crohn ' s disease ( Claramunt et al . , 2009 ) has been documented . Enhanced bioavailability of cur - cumin in the near future is likely to bring this promising natural product to the forefront of therapeutic agents for the treatment of human disease ."
    [Show abstract] [Hide abstract]
    ABSTRACT: Spices, like vegetables, fruit, and medicinal herbs, are known to possess a variety of antioxidant effects and other biological activities. Phenolic compounds in these plant materials are closely associated with their antioxidant activity, which is mainly due to their redox properties and their capacity to block the production of reactive oxygen species. More recently, their ability to interfere with signal transduction pathways involving various transcription factors, protein kinases, phosphatases, and other metabolic enzymes has also been demonstrated. Many of the spice-derived compounds which are potent antioxidants are of great interest to biologists and clinicians because they may help protect the human body against oxidative stress and inflammatory processes. It is important to study the bioactive compounds that can modulate target functions related to defence against oxidative stress, and that might be used to achieve health benefits individually. In the present review, an attempt has been made to summarize the most current scientific evidence about the in vitro and in vivo effects of the bioactive compounds derived from herbs and spices, focused on anti-inflammatory and antioxidant effects, in order to provide science-based evidence for the traditional uses and develop either functional foods or nutraceuticals.
    Critical reviews in food science and nutrition 01/2013; 53(9):943-53. DOI:10.1080/10408398.2011.574802 · 5.55 Impact Factor
  • Source
    • "Although the number of clinical trials is still limited compared to the numerous preclinical studies, several phase I or pharmacokinetic studies have been conducted with curcumin and found no dose limiting toxicity (DLT) up to at least 12 g/day when administered orally in both healthy volunteers (Lao et al., 2006; Vareed et al., 2008) and cancer patients (Cheng et al., 2001; Garcea et al., 2005; Sharma et al., 2004). Minor toxicities of Grade 1-2 diarrhea and nausea have been reported, probably due to the oral intake of a bulky volume of curcumin at one time. "
    Pancreatic Cancer - Molecular Mechanism and Targets, 12/2011; , ISBN: 978-953-51-0410-0